Literature DB >> 21054587

Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.

K C Epps1, R L Wilensky.   

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA₂) is at the crossroads of lipid metabolism and the inflammatory response. It is produced by inflammatory cells, bound to LDL and other lipoproteins, and once in the arterial wall facilitates hydrolysis of phospholipids. Elevated serum levels of Lp-PLA₂ have been associated with increased cardiovascular risk in healthy populations and in patients with known vascular disease. Here, we review the role of Lp-PLA₂ in the development of atherosclerosis and progression to unstable disease, the utility of Lp-PLA₂ as a risk predictor for coronary and carotid events and the potential clinical benefit of pharmacologic inhibition of Lp-PLA₂.
© 2010 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054587     DOI: 10.1111/j.1365-2796.2010.02297.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  23 in total

Review 1.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk.

Authors:  Zeynep Gungor; Erdembileg Anuurad; Byambaa Enkhmaa; Wei Zhang; Kyoungmi Kim; Lars Berglund
Journal:  Atherosclerosis       Date:  2012-05-08       Impact factor: 5.162

3.  High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy.

Authors:  Stuart G Snowden; Dmitry Grapov; Magnus Settergren; Fabio Luiz D'Alexandri; Jesper Z Haeggström; Oliver Fiehn; Tuulia Hyötyläinen; Theresa L Pedersen; John W Newman; Matej Orešič; John Pernow; Craig E Wheelock
Journal:  Circ Cardiovasc Genet       Date:  2014-12

4.  Prognostic value of color Doppler ultrasound, D-dimer, and Lp-PLA2 levels in carotid atherosclerotic stenosis.

Authors:  Yu Kong; Ying Kong; Yunyi Dai; Jianping Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

5.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

6.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10

7.  Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.

Authors:  Bao-Feng Chen; Yun Deng; Xin Xu; Shao-Chun Ma; Liang-Qiu Tang; Jin-Feng Chen; Wei-Qian Sun; Su-Fang Liu; Jia-Rong Liang
Journal:  Acta Cardiol Sin       Date:  2018-05       Impact factor: 2.672

8.  Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.

Authors:  Petr Ostadal; Dagmar Vondrakova; Andreas Kruger; Marek Janotka; Hana Psotova; Miroslav Prucha
Journal:  Lipids Health Dis       Date:  2012-11-10       Impact factor: 3.876

9.  Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females.

Authors:  Danjie Jiang; Dawei Zheng; Lingyan Wang; Yi Huang; Haibo Liu; Leiting Xu; Qi Liao; Panpan Liu; Xinbao Shi; Zhaoyang Wang; Lebo Sun; Qingyun Zhou; Ni Li; Limin Xu; Yanping Le; Meng Ye; Guofeng Shao; Shiwei Duan
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease.

Authors:  Limin Xu; Jianqing Zhou; Stephanie Huang; Yi Huang; Yanping LE; Danjie Jiang; Feiming Wang; Xi Yang; Weifeng Xu; Xiaoyan Huang; Changzheng Dong; Lina Zhang; Meng Ye; Jiangfang Lian; Shiwei Duan
Journal:  Exp Ther Med       Date:  2013-01-21       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.